Other

Consejo Superior De Investigaciones Cientificas

Pharmacia & Upjohn Ab

Pharmacia Ab

Universidad Autónoma De Madrid

Carlos Martinez Alonso

Leonor Kremer Baron

Jose Mario Garcia

Jose Miguel Frade

Peter Lind

Antonio Bernad

Terje Kalland

Pilar Lauzurica Gómez

Jos&eacute; Mario Mellado Garcia

Javier Vega Ramos

Francisco Sanchez-Madrid

David Sancho Madrid

Pablo Engel Rocamora

Jos&eacute; Miguel Rodriguez Frade

Enric Esplugues Artola

Yngve Elof Hansson

Fernando Rojo

Guido Peter Kroemer

Vincente D&iacute;as

JoseAngel Gonzalo

Maria Vela Cuenca

Ana Franco Villanueva

Laura Carramolino Fitera

Juan C Alonso

Jose Alberto Garcia Sanz

Sonia Chamorro Perez

Disclosed are methods of treating subjects having disorders or conditions characterized by an unwanted immune response including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.

Immune regulation based on the depletion of CD69+ cells

Use of beta recombinase in eukaryotic cells, especially for transgenic work

The present invention relates to a method for determinating cytokine receptor, especially growth hormone receptor (GHR), activation, by the use of an antibody capable of discriminating between an activated and an inactive cytokine receptor conformation, especially GHR or growth hormone binding protein (GHBP) conformation, the method comprising: contacting the antibody and the cytokine receptor to form a complex, contacting a candidate ligand to the complex, measuring the antibody binding to inactive cytokine receptor and thereby discriminating between an activated and an inactive conformation. The invention also relates to an antibody directed to the hinge spanning subdomains I and II of the growth hormone receptor extracellular region and which is capable of discriminating between an activated and an inactive receptor conformation. The invention also relates to the use of the antibody for e.g. characterization of growth hormone receptor interactions and for screening for compounds stabilising die dimerization of GHR.

Method for determining cytokine receptor activation by the use of an antibody

The invention relates to antibodies which is capable of binding the monocyte chemoattractant protein 1 (MCP-1) receptor CCR2, especially those which are capable of acting either as an antagonist or agonist. The claimed antobodies can be used for in vitro and/or in vivo diagnostic, for screening and detection of tissues and classes of cells expressing the MCP-1 receptor, for screening for new drugs and for therapeutic use. The invention also relates to a preparation comprising the claimed antibody and a micro-organism or cell-line capable of producing the claimed antibody.

Agonist and antagonist antibodies to the chemokine receptor-2 (CCR2)

The invention relates to monoclonal antibody capable of specific binding to the molecular weight of 20 kDa variant of human growth hormone. This monoclonal antibody has no substantial binding to hGH of molecular weight 22 kDa. The invention also relates to the use of this monoclonal antibody for measurement of hGH 20K, especially in body fluids. The antibodies can be used for detection and quantification of hGH 20K, especially in serum.

Monoclonal antibody

Use of quinoline-3-carboxamide compounds for inhibiting the production

Growing community of inventors

Madrid, Spain

Carlos Martinez Alonso